ArticleFrontiers in immunology2023

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy.

Chad Pickering et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.